title: Cost-effectiveness analysis of the use of palivizumab in the prophylaxis of preterm patients in Mexico.
abstract: OBJECTIVE
  The study evaluated the incremental cost-effectiveness ratio (ICER) of the prophylaxis of palivizumab, for the reduction of complications associated to the respiratory syncytial virus in preterm patients in Mexico.
  
  
  METHODS
  A decision tree was developed in preterm groups [<29 and 29-32 weeks of gestational age (wGA)], by using epidemiological and cost local data; the effectiveness was obtained with a systematic review. Patients were evaluated according to their life expectancy. Mexican Health System perspective was used. Effectiveness measures employed were LYG and QALYs. The costs are reported in USD 2009.
  
  
  RESULTS
  ICERs per LYG resulted on values of USD $25,029 and USD $29,637 for <29 wGA and 29-32 wGA respectively, whereas ICERs per QALYs obtained in the model accounted for USD $17,532 and USD $20,760.
  
  
  CONCLUSIONS
  Palivizumab prophylaxis for preterm newborn patients ≤32 weeks of age resulted in a cost-effective alternative.
authors.affiliation: Dirección de Investigación, Centro de Estudios Económicos y Sociales en Salud, Hospital Infantil de México Federico Gómez, Secretaría de Salud, México, DF.
authors.forename: Guillermo
authors.initials: G
authors.lastname: Salinas-Escudero
authors.forename: Silvia
authors.initials: S
authors.lastname: Martínez-Valverde
authors.forename: Alfonso
authors.initials: A
authors.lastname: Reyes-López
authors.forename: Juan
authors.initials: J
authors.lastname: Garduño-Espinosa
authors.forename: Onofre
authors.initials: O
authors.lastname: Muñoz-Hernández
authors.forename: Víctor
authors.initials: V
authors.lastname: Granados-García
authors.forename: Kely
authors.initials: K
authors.lastname: Rely
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000191:economics* / Q000627:therapeutic use*; D000998:Antiviral Agents / Q000191:economics* / Q000627:therapeutic use*; D003362:Cost-Benefit Analysis; D003663:Decision Trees; D006801:Humans; D007231:Infant, Newborn; D007234:Infant, Premature; D007235:Infant, Premature, Diseases / Q000517:prevention & control*; D008800:Mexico; D000069455:Palivizumab; D018357:Respiratory Syncytial Virus Infections / Q000191:economics* / Q000517:prevention & control*
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000998:Antiviral Agents; D000069455:Palivizumab